Dyne Therapeutics (DYN) had its price target lowered by HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Dyne Therapeutics (DYN) was given a new $38.00 price target by Chardan Capital.
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing [Yahoo! Finance]
Dyne Therapeutics (DYN) had its "overweight" rating reaffirmed by Morgan Stanley.
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]